GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accuray Inc (NAS:ARAY) » Definitions » Cash Conversion Cycle

Accuray (Accuray) Cash Conversion Cycle : 213.68 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Accuray Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Accuray's Days Sales Outstanding for the three months ended in Dec. 2023 was 65.85.
Accuray's Days Inventory for the three months ended in Dec. 2023 was 195.2.
Accuray's Days Payable for the three months ended in Dec. 2023 was 47.37.
Therefore, Accuray's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 213.68.


Accuray Cash Conversion Cycle Historical Data

The historical data trend for Accuray's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accuray Cash Conversion Cycle Chart

Accuray Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 202.15 246.88 237.74 218.03 207.17

Accuray Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 219.54 204.52 190.74 227.30 213.68

Competitive Comparison of Accuray's Cash Conversion Cycle

For the Medical Devices subindustry, Accuray's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accuray's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accuray's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Accuray's Cash Conversion Cycle falls into.



Accuray Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Accuray's Cash Conversion Cycle for the fiscal year that ended in Jun. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=68.99+178.62-40.44
=207.17

Accuray's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=65.85+195.2-47.37
=213.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accuray  (NAS:ARAY) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Accuray Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Accuray's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Accuray (Accuray) Business Description

Traded in Other Exchanges
Address
1240 Deming Way, Madison, WI, USA, 53717
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Executives
Gina Corradetti officer: VP, Corporate Controller 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Ali Pervaiz officer: SVP Chief Financial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Jesse Chew officer: SVP and General Counsel 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Sandeep Chalke officer: SVP, Chief Commercial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Suzanne C Winter officer: SVP & Chief Commercial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Patrick Spine officer: SVP, Chief Admin Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Michael Hoge officer: Senior VP Global Operations 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Kill director VIRTUAL RADIOLOGIC CORPORATION, 5995 OPUS PARKWAY, SUITE 200, MINNETONKA MN 55343
Brandon W Green officer: Chief Financial Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Franco N Palomba officer: VP, Chief Accounting Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Byron C Scott director 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Joshua Levine officer: President & CEO 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Mika Nishimura director 471 EL CAMINO REAL, SANTA CLARA CA 95050
Joseph E Whitters director
Shigeyuki Hamamatsu officer: VP, Finance and CAO 1875 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043